Five biopsy specimens from the proximal part of the tumor reliably determine HER2 protein expression status in gastric cancer

Gastric Cancer

Volumn 19, Issue 2, 2016, Pages 553-560

  Tominaga, Naoyuki ^a,b   Gotoda, Takuji ^a   Hara, Megumi ^c   Hale, Matthew D ^d   Tsuchiya, Takayoshi ^a   Matsubayashi, Jun ^a   Kono, Shin ^a   Kusano, Chika ^a   Itoi, Takao ^a   Fujimoto, Kazuma ^b   Moriyasu, Fuminori ^a   Grabsch, Heike I ^d,e,f  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b SAGA UNIVERSITY   (Japan)

^c SAGA UNIVERSITY   (Japan)

^d UNIVERSITY OF LEEDS   (United Kingdom)

^e MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^f MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Gastric cancer; HER2 expression; Virtual biopsy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; TUMOR MARKER;

AGED; ANUS; ARTICLE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MOUTH; PILOT STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; STOMACH CANCER; TISSUE SECTION; TUMOR BIOPSY; TUMOR CELL; TUMOR LOCALIZATION; ADENOCARCINOMA; BIOPSY; GASTRECTOMY; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES; STOMACH NEOPLASMS; VERY ELDERLY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BIOPSY; GASTRECTOMY; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; RECEPTOR, ERBB-2; STOMACH NEOPLASMS;

EID: 84929687537     PISSN: 14363291     EISSN: 14363305     Source Type: Journal    
DOI: 10.1007/s10120-015-0502-3     Document Type: Article

References (21)

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase no. 11. Lyon: International Agency for Research on Cancer; 2013.
2. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358(1):36–46. doi:10.1056/NEJMoa073149.
3. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97. doi:10.1016/s0140-6736(10)61121-x.
4. Waddell T, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D. Gastric cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):57–63. doi:10.1093/annonc/mdt344.
5. Ajani JA, Bentrem DJ, Besh S, D’Amico TA, Das P, Denlinger C, et al. Gastric cancer, version 2.2013: featured updates to the NCCN guidelines. J Natl Compr Cancer Netw. 2013;11(5):531–46.
6. Rüschoff J, Hanna W, Bilous M, Hofmann M, Osamura RY, Penault-Llorca F, et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol. 2012;25(5):637–50. doi:10.1038/modpathol.2011.198.
7. Tanner M, Hollmén M, Junttila TT, Kapanen AI, Tommola S, Soini Y, et al. Amplification of HER2 in gastric carcinoma: association with topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol. 2005;16(2):273–8. doi:10.1093/annonc/mdi064.
8. Gómez-Martin C, Garralda E, Echarri MJ, Ballesteros A, Arcediano A, Rodriguez-Peralto JL, et al. HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer. J Clin Pathol. 2012;65(8):751–7. doi:10.1136/jclinpath-2012-200774.
9. Kunz PL, Mojtahed A, Fisher GA, Ford JM, Chang DT, Balise RR, et al. HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment. Appl Immunohistochem Mol Morphol. 2012;20(1):13–24. doi:10.1097/PAI.0b013e31821c821c.
10. Janjigian YY, Werner D, Pauligk C, Steinmetz K, Kelsen DP, Jager E, et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA international collaborative analysis. Ann Oncol. 2012;23(10):2656–62. doi:10.1093/annonc/mds104.
11. Grabsch H, Sivakumar S, Gray S, Gabbert HE, Müller W. HER2 expression in gastric cancer: rare, heterogeneous and of no prognostic value––conclusions from 924 cases of two independent series. Cell Oncol. 2010;32(1–2):57–65. doi:10.3233/CLO-2009-0497.
12. Fan XS, Chen JY, Li CF, Zhang YF, Zhang YF, Meng FQ, Wu HY, et al. Differences in HER2 over-expression between proximal and distal gastric cancers in the Chinese population. World J Gastroenterol. 2013;19(21):3316–23. doi:10.3748/wjg.v19.i21.3316.
13. Yan B, Yau EX, Choo SN, Ong CW, Yong KJ, Pang B, et al. Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples. J Clin Pathol. 2011;64(10):880–3. doi:10.1136/jclinpath-2011-200009.
14. Yano T, Doi T, Ohtsu A, Boku N, Hashizume K, Nakanishi M, et al. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep. 2006;15(1):65–71.
15. Yang J, Luo H, Li Y, Li J, Cai Z, Su X, et al. Intratumoral heterogeneity determines discordant results of diagnostic tests for human epidermal growth factor receptor (HER) 2 in gastric cancer specimens. Cell Biochem Biophys. 2012;62(1):221–8. doi:10.1007/s12013-011-9286-1.
16. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14(2):101–12. doi:10.1007/s10120-011-0041-5.
17. Hofmann M, Stoss O, Shi D, Büttner R, van de Vijver M, Kim W, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008;52(7):797–805. doi:10.1111/j.1365-2559.2008.03028.x.
18. Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumors. 7th ed. Chichester: Wiley; 2009.
19. Fléjou JF. WHO Classification of digestive tumors: the fourth edition. Ann Pathol. 2011;31(5 Suppl):27–31. doi:10.1016/j.annpat.2011.08.001.
20. Ieni A, Barresi V, Giuffrè G, Caruso RA, Lanzafame S, Villari L, et al. HER2 status in advanced gastric carcinoma: a retrospective multicentric analysis from Sicily. Oncol Lett. 2013;6(6):1591–4.
21. Inokuchi K, Sugimachi K. Growth patterns of gastric cancer. In: Nishi M, Ichikawa H, Nakajima T, Maruyama K, Tahara E, editors. Gastric cancer. Tokyo: Springer Japan; 1993. p 88–101.